Boston Scientific Corp (BSX)vsiRhythm Technologies Inc (IRTC)
BSX
Boston Scientific Corp
$45.98
-0.09%
HEALTHCARE · Cap: $63.87B
IRTC
iRhythm Technologies Inc
$122.44
+4.32%
HEALTHCARE · Cap: $3.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 2516% more annual revenue ($20.61B vs $787.85M). BSX leads profitability with a 17.3% profit margin vs -3.5%. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
IRTC
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-23.2%
Fair Value
$37.36
Current Price
$45.98
$8.62 premium
Intrinsic value data unavailable for IRTC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Revenue surging 25.7% year-over-year
Areas to Watch
Distress zone — elevated risk
0.0% earnings growth
Trading at 24.9x book value
ROE of -17.2% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : IRTC
The strongest argument for IRTC centers on Revenue Growth. Revenue growth of 25.7% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : IRTC
The primary concerns for IRTC are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 4.52 is elevated, increasing financial risk.
Key Dynamics to Monitor
BSX profiles as a mature stock while IRTC is a growth play — different risk/reward profiles.
IRTC carries more volatility with a beta of 1.27 — expect wider price swings.
IRTC is growing revenue faster at 25.7% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 30/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
iRhythm Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
iRhythm Technologies, Inc., a digital healthcare company, offers ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company is headquartered in San Francisco, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?